{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:27:41Z","timestamp":1790767661985,"version":"4.1.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Cancer patients have a heightened susceptibility to anxiety and depressive disorders, which significantly impact the effectiveness of cancer treatments and long-term quality of life. This study aimed to compare the efficacy of different antidepressants in cancer and non-cancer patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 610 patients diagnosed with depressive episodes and\/or anxiety disorders were retrospectively included and divided into a cancer group and a non-cancer control group. Antidepressants used included escitalopram, duloxetine, sertraline, venlafaxine, and vortioxetine, combined with trazodone or not. The Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder Questionnaire-7 (GAD-7) scores were used to evaluate the efficacy after 4 weeks and 8 weeks of systematic antidepressants treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared to the non-cancer group, the cancer group had higher proportions of females, older individuals, and patients with poor sleep quality, while reporting fewer somatic symptoms at baseline (all <jats:italic>p<\/jats:italic> &amp;lt; 0.05). PHQ-9 and GAD-7 scores in cancer patients treated with antidepressants were significantly lower than baseline at week 4 and week 8 (all <jats:italic>p<\/jats:italic> &amp;lt; 0.05). The sertraline group demonstrated significantly less improvement in GAD-7 scores at week 4 and in both GAD-7 and PHQ-9 scores at week 8 compared to the escitalopram group, while duloxetine, venlafaxine, and vortioxetine showed comparable efficacy to escitalopram. Antidepressants combined with trazodone showed significant improvement in PHQ-9 scores at week 4 compared to those without trazodone. The gynecological cancer group showed significantly more improvement in GAD-7 and PHQ-9 scores at week 4 and 8 compared to breast cancer patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Antidepressant treatment in cancer patients with anxiety and depression is as effective as in non-cancer patients. The efficacy of escitalopram is comparable to duloxetine, venlafaxine, and vortioxetine, all of which outperformed sertraline in cancer patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnins.2024.1485179","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T13:07:27Z","timestamp":1730293647000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy comparison of five antidepressants in treating anxiety and depression in cancer and non-cancer patients"],"prefix":"10.3389","volume":"18","author":[{"given":"Kuan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1200\/JCO.23.00293","article-title":"Management of anxiety and depression in adult survivors of cancer: ASCO guideline update.","volume":"41","author":"Andersen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12484","article-title":"Duloxetine and escitalopram for hot flushes: Efficacy and compliance in breast cancer survivors.","volume":"27","author":"Biglia","year":"2018","journal-title":"Eur. J. Cancer Care"},{"key":"B3","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41583-023-00729-2","article-title":"Central regulation of stress-evoked peripheral immune responses.","volume":"24","author":"Chan","year":"2023","journal-title":"Nat. Rev. Neurosci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis.","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s12020-021-02786-y","article-title":"Distress, anxiety, depression and unmet needs in thyroid cancer survivors: A longitudinal study.","volume":"74","author":"Dionisi-Vici","year":"2021","journal-title":"Endocrine"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1002\/pon.4681","article-title":"The generalized anxiety disorder screener (GAD-7) and the anxiety module of the hospital and depression scale (HADS-A) as screening tools for generalized anxiety disorder among cancer patients.","volume":"27","author":"Esser","year":"2018","journal-title":"Psychooncology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.neuron.2023.10.020","article-title":"A stress-sensitive frontostriatal circuit supporting effortful reward-seeking behavior.","volume":"112","author":"Fetcho","year":"2023","journal-title":"Neuron"},{"key":"B8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.bbi.2016.03.025","article-title":"Inflammatory markers are associated with decreased psychomotor speed in patients with major depressive disorder.","volume":"56","author":"Goldsmith","year":"2016","journal-title":"Brain Behav. Immun."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796019000829","article-title":"Psychiatric and psychosocial implications in cancer care: The agenda of psycho-oncology.","volume":"29","author":"Grassi","year":"2020","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02307-6","article-title":"Author Correction: Suicide risk and mortality among patients with cancer.","volume":"29","author":"Heinrich","year":"2023","journal-title":"Nat. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/nature07455","article-title":"The molecular neurobiology of depression.","volume":"455","author":"Krishnan","year":"2008","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/00006842-200203000-00008","article-title":"The PHQ-15: Validity of a new measure for evaluating the severity of somatic symptoms.","volume":"64","author":"Kroenke","year":"2002","journal-title":"Psychosom. Med."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.101182","article-title":"Depression in patients with hematologic malignancies: The current landscape and future directions.","volume":"65","author":"Kuczmarski","year":"2024","journal-title":"Blood Rev."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011108.pub3","article-title":"Hydromorphone for cancer pain.","volume":"8","author":"Li","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"B15","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1080\/00273171.2024.2350236","article-title":"Linear mixed-effects models for dependent data: Power and accuracy in parameter estimation.","volume":"59","author":"Liu","year":"2024","journal-title":"Multivar. Behav. Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/j.2051-5545.2011.tb00061.x","article-title":"The heterogeneity of depression.","volume":"180","author":"Lynall","year":"2023","journal-title":"Am. J. Psychiatry"},{"key":"B17","doi-asserted-by":"crossref","first-page":"E191","DOI":"10.1503\/cmaj.110829","article-title":"Optimal cut-off score for diagnosing depression with the patient health questionnaire (PHQ-9): A meta-analysis.","volume":"184","author":"Manea","year":"2012","journal-title":"CMAJ"},{"key":"B18","doi-asserted-by":"crossref","first-page":"434","DOI":"10.6004\/jnccn.2019.7374","article-title":"Tumor mutation burden and depression in lung cancer: Association with inflammation.","volume":"18","author":"Mcfarland","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"B19","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1470-2045(11)70002-X","article-title":"Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: A meta-analysis of 94 interview-based studies.","volume":"12","author":"Mitchell","year":"2011","journal-title":"Lancet Oncol."},{"key":"B20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.34172\/jcs.2021.021","article-title":"Sleep quality and cancer-related fatigue in patients with cancer.","volume":"10","author":"Momayyezi","year":"2021","journal-title":"J. Car. Sci."},{"key":"B21","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4088\/JCP.v67n0217","article-title":"A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.","volume":"67","author":"Musselman","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"B22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/978-1-59745-530-5_11","article-title":"Linear mixed effects models.","volume":"404","author":"Oberg","year":"2007","journal-title":"Methods Mol. Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3109\/09540261.2010.492391","article-title":"Gender differences in depression.","volume":"22","author":"Parker","year":"2010","journal-title":"Int. Rev. Psychiatry"},{"key":"B24","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s10549-019-05271-3","article-title":"Global prevalence of depression among breast cancer patients: A systematic review and meta-analysis.","volume":"176","author":"Pilevarzadeh","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"B25","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/cac2.12197","article-title":"Cancer incidence, mortality, and burden in China: A time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020.","volume":"41","author":"Qiu","year":"2021","journal-title":"Cancer Commun."},{"key":"B26","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1176\/appi.ajp.2012.12040474","article-title":"model of placebo response in antidepressant clinical trials.","volume":"170","author":"Rutherford","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"B27","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/pon.6079","article-title":"Network analysis of depression in prostate cancer patients: Implications for assessment and treatment.","volume":"32","author":"Sharpley","year":"2023","journal-title":"Psychooncology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/0284186X.2021.1992008","article-title":"Prevalence of mental disorders in patients with cancer compared to matched controls - secondary analysis of two nationally representative surveys.","volume":"61","author":"Vehling","year":"2022","journal-title":"Acta Oncol."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011006.pub3","article-title":"Antidepressants for the treatment of depression in people with cancer.","volume":"3","author":"Vita","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"B31","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003901","article-title":"Depression and anxiety in prostate cancer: A systematic review and meta-analysis of prevalence rates.","volume":"4","author":"Watts","year":"2014","journal-title":"BMJ Open"},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.1007\/s11920-017-0816-4","article-title":"Effects of antidepressants on sleep.","volume":"19","author":"Wichniak","year":"2017","journal-title":"Curr. Psychiatry Rep."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-023-05382-8","article-title":"Escitalopram versus other antidepressive agents for major depressive disorder: A systematic review and meta-analysis.","volume":"23","author":"Yin","year":"2023","journal-title":"BMC Psychiatry"}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2024.1485179\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T13:07:47Z","timestamp":1730293667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2024.1485179\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":33,"alternative-id":["10.3389\/fnins.2024.1485179"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2024.1485179","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]},"article-number":"1485179"}}